A Malone1, G Kennedy2,3, L Storey3, A O'Marcaigh3,4, M McDermott3, A M Broderick3, O P Smith2,3,4. 1. Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland. andreammalone@gmail.com. 2. University College Dublin, Dublin, Ireland. 3. Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland. 4. Trinity College Dublin, Dublin, Ireland.
Abstract
BACKGROUND: Post-transplant lymphoproliferative disease (PTLD) is a serious complication of both solid organ and haematopoietic stem cell transplantation in children. Its incidence has increased over the last decade as a result of more potent immunosuppressive regimens. Many treatments have been explored however optimal therapy remains controversial. AIMS: We report on the diagnosis, treatment and outcome of ten patients who were diagnosed with PTLD in Our Lady's Hospital for Sick Children in Dublin between 2004 and 2015 inclusive. METHODS: Data were collected by retrospective review of patient medical records. RESULTS: 9 out of ten of our patients are alive and disease free following treatment for PTLD with rituximab alone or in combination with chemotherapy. CONCLUSION: The outcome of paediatric patients treated for PTLD at our institution is at least comparable to published international series and supports the use of rituximab ± low dose chemotherapy in the treatment of this malignancy.
BACKGROUND: Post-transplant lymphoproliferative disease (PTLD) is a serious complication of both solid organ and haematopoietic stem cell transplantation in children. Its incidence has increased over the last decade as a result of more potent immunosuppressive regimens. Many treatments have been explored however optimal therapy remains controversial. AIMS: We report on the diagnosis, treatment and outcome of ten patients who were diagnosed with PTLD in Our Lady's Hospital for Sick Children in Dublin between 2004 and 2015 inclusive. METHODS: Data were collected by retrospective review of patient medical records. RESULTS: 9 out of ten of our patients are alive and disease free following treatment for PTLD with rituximab alone or in combination with chemotherapy. CONCLUSION: The outcome of paediatric patients treated for PTLD at our institution is at least comparable to published international series and supports the use of rituximab ± low dose chemotherapy in the treatment of this malignancy.
Authors: Thomas G Gross; John C Bucuvalas; Julie R Park; Timothy C Greiner; Steven H Hinrich; Stuart S Kaufman; Alan N Langnas; Ruth A McDonald; Frederick C Ryckman; Byers W Shaw; Debra L Sudan; James C Lynch Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: Lode J Swinnen; Michael LeBlanc; Thomas M Grogan; Leo I Gordon; Patrick J Stiff; Alan M Miller; Yvette Kasamon; Thomas P Miller; Richard I Fisher Journal: Transplantation Date: 2008-07-27 Impact factor: 4.939